Freedom Broker initiates IRadimed stock coverage with buy rating
Freedom Broker has initiated coverage on IRadimed Corp (NASDAQ:IRMD) with a buy rating and a price target of $116.00, implying a potential upside of 20% from its current trading price of $96.53. The company, which operates profitably and pays dividends, specializes in non-magnetic MRI-compatible IV infusion pumps and patient monitoring systems, being the sole provider of both. This follows a strong Q4 2025 performance where IRadimed surpassed analyst expectations for both EPS and revenue.
Freedom Broker initiates IRadimed stock coverage with buy rating
Freedom Broker has initiated coverage on IRadimed Corp (NASDAQ:IRMD) with a buy rating and a price target of $116.00, suggesting a 20% potential upside from its current trading price of $96.53. The company, a medical technology firm specializing in non-magnetic MRI-compatible IV infusion pumps and patient monitoring systems, recently reported Q4 2025 earnings that exceeded analyst expectations. Despite trading at a high P/E ratio of 53.4, InvestingPro Tips rates IRadimed's financial health as "GREAT."
Iradimed CEO Susi sells $712k in shares
IRADIMED CORP CEO Roger E. Susi sold 7,400 shares of common stock for a total of $712,614 on March 30, 2026, through a pre-arranged trading plan. The sales occurred at varied prices between $94.36 and $97.16, with the stock trading near its 52-week high but considered overvalued by InvestingPro's fair value assessment. Despite the insider sale, Iradimed recently reported strong Q4 2025 financial results, surpassing analyst expectations for EPS and revenue.
Iradimed CEO Susi sells $712k in shares
Iradimed CEO Roger E. Susi sold 7,400 shares of the company's common stock for a total of $712,614 through a pre-arranged trading plan. These sales occurred on March 30, 2026, with prices ranging from $94.36 to $97.16 per share. Despite the sale, Susi retains significant indirect holdings in the company, which recently reported strong Q4 2025 financial results, exceeding analyst expectations.
Insider trust tied to IRADIMED (IRMD) CEO sells 7,500 shares under 10b5-1
A trust associated with IRADIMED CORP (IRMD) CEO Roger E. Susi, The Phillip Susi 2008 Dynasty Trust, sold 7,500 shares of common stock on March 30, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales occurred in three transactions at weighted average prices ranging from $94.81 to $96.53. After these sales, the Dynasty Trust still holds 2,225,000 shares, with additional indirect holdings reported in other trusts.
CEO Of iRadimed Sold $752K In Stock
iRadimed's CEO, Roger E Susi, sold 7,500 shares of company stock worth $752,609 on March 25, as detailed in a recent SEC filing. The company (NASDAQ: IRMD) shows positive financial milestones, including 17.03% revenue growth and a high gross margin of 75.06%, but its EPS lags and its market capitalization is below industry averages. Insider transactions, while not primary investment drivers, offer valuable insights into a company's prospects.
Roger Susi Sells 2,500 Shares of iRadimed (NASDAQ:IRMD) Stock
iRadimed Corporation CEO Roger Susi sold 2,500 shares of the company's stock on March 24th for $250,700, reducing his ownership by 0.11% to 2,232,500 shares. The company recently exceeded Q4 earnings estimates, raised its Q1 and FY 2026 guidance, and increased its quarterly dividend. Analysts currently have a "Moderate Buy" rating on IRMD with an average price target of $120.
IRADIMED (NASDAQ: IRMD) CEO sells 7,500 trust-held shares under plan
IRADIMED CEO Roger E. Susi sold 7,500 shares of common stock indirectly through the Phillip Susi 2008 Dynasty Trust on March 23–24, 2026, at prices around $100 per share. These sales were pre-arranged under a Rule 10b5-1 trading plan adopted on November 5, 2025. Despite the sales, significant indirect holdings remain in various trusts, indicating routine portfolio management rather than opportunistic market timing.
IRadimed Corp 、1株当たり41セントの利益を予想 - Earnings Preview
IRadimed Corp (IRMD) is expected to report increased quarterly revenue and earnings per share for the period ending March 31, 2025. Analysts project a 9.9% revenue increase to $19.33 million and earnings per share of $0.41. The current average analyst rating for IRadimed Corp is "buy," with a median price target of $71.00.
Iradimed CEO Susi sells $763k in IRMD stock
Roger E. Susi, CEO, President, and Chairman of IRADIMED CORP (NASDAQ:IRMD), sold 7,500 shares of company stock for approximately $762,970 between March 16 and March 17, 2026. These sales occurred while IRMD stock traded near its 52-week high, with InvestingPro analysis suggesting the stock is overvalued. Susi's transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 2,500 Shares
iRadimed (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the company's stock on March 17th for a total of $256,075, reducing his ownership by 0.11% to 2,240,000 shares. The company recently reported strong Q4 results, exceeding revenue and EPS estimates, and issued positive guidance for Q1 and FY 2026. iRadimed also increased its quarterly dividend and currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $120.
Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock
Roger Susi, CEO of iRadimed (NASDAQ:IRMD), sold 5,000 shares of the company's stock on March 16th at an average price of $101.38, totaling $506,900. This sale represents a 0.22% reduction in his holdings, leaving him with 2,242,500 shares. The company recently reported strong quarterly earnings, exceeding analyst expectations, and increased its quarterly dividend to $0.20 per share.
Insider trust linked to IRADIMED (NASDAQ: IRMD) sells 7,500 shares
A trust linked to IRADIMED CEO Roger E. Susi sold 7,500 shares of the company's common stock on March 16-17, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales were executed at weighted average prices between $101.18 and $102.43 per share. Despite these sales, the Phillip Susi 2008 Dynasty Trust still holds 2,240,000 shares, with additional substantial indirect holdings through other trusts, indicating a small liquidity or diversification transaction.
IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
IRADIMED CORPORATION (NASDAQ: IRMD) announced its participation in the 38th Annual Roth Conference. CEO Roger Susi and CFO Jack Glenn will host one-on-one meetings with investors on March 22 and 24, 2026, in Laguna Niguel, CA. The company is known for its MRI-compatible medical devices, including an IV infusion pump system and a patient vital signs monitoring system.
IRADIMED execs heading to Roth investor conference in California
IRADIMED CORPORATION (NASDAQ: IRMD) will participate in the 38th Annual Roth Conference on March 22 and March 24, 2026. CEO Roger Susi and CFO Jack Glenn will conduct one-on-one investor meetings at the Ritz-Carlton, Laguna Niguel, CA. This event provides an opportunity for investors to engage directly with senior management about the company's strategy and financial priorities.
Assessing IRADIMED (IRMD) Valuation After Strong Long Term Returns And A High P/E Multiple
IRADIMED (IRMD) has shown strong long-term returns with a 91.95% one-year and 346.3% five-year total shareholder return, despite recent short-term declines. The company is estimated to be 17.5% undervalued with a fair value of US$120, driven by expected higher gross margins from its new 3870 pump and operational leverage. However, its high P/E ratio of 56.3x compared to the industry average of 27.7x raises concerns about potential pressure if sentiment cools.
Assessing IRADIMED (IRMD) Valuation After Strong Long Term Returns And A High P/E Multiple
IRADIMED (IRMD) has shown strong long-term returns despite recent short-term volatility. While its shares are considered 17.5% undervalued with a fair value estimate of US$120 due to strong revenue, resilient margins, and analyst targets, its high P/E ratio of 56.3x compared to the industry average raises concerns about potential cooling sentiment. Investors are advised to examine the underlying data and potential risks, such as a narrow product lineup or supply chain issues, before making investment decisions.
IRADIMED (IRMD) CEO trust sells 7,500 shares under 10b5-1 plan
IRADIMED CORP's CEO, Roger E. Susi, reported that the Phillip Susi 2008 Dynasty Trust indirectly sold 7,500 shares of company common stock in open-market transactions on March 9 and March 10, 2026. These sales, executed under a pre-arranged Rule 10b5-1 trading plan, amounted to approximately $100 per share. Following these transactions, the trust still holds over 2.2 million shares, indicating a modest reduction in position and routine portfolio management rather than a significant change in insider sentiment.
Planned sale: IRADIMED (IRMD) family trust unloads 7,500 shares
IRADIMED CEO Roger E. Susi's family trust, the Phillip Susi 2008 Dynasty Trust, sold 7,500 shares of company stock on March 6, 2026, as part of a Rule 10b5-1 trading plan. The sales occurred at weighted average prices of $98.25 and $99.12 per share. Following these transactions, other related trusts, including the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust, still hold substantial indirect positions.
IRADIMED (IRMD) Chief Commercial Officer receives 1,150 RSU equity grant
IRADIMED Corp (IRMD) Chief Commercial Officer Jeff Chiprin was granted 1,150 restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan. These RSUs, which convert to common stock on a one-for-one basis, will vest in three equal annual installments starting December 7, 2026. This equity award is a non-cash grant designed to align executive compensation with long-term company performance.
Trust plans 2.36M IRMD share resale; recent 5,000-share trades (IRMD)
The Phillip Susi 2008 Dynasty Trust has filed a Form 144 indicating an intent to sell 2,362,500 shares of Iradimed Corporation (IRMD) common stock. This filing also details eight separate dispositions of 5,000 shares each by the trust between December 8, 2025, and January 26, 2026, with proceeds listed for each transaction. This indicates a private resale under Rule 144 rather than an issuer issuance.
HighTower Advisors LLC Sells 20,000 Shares of iRadimed Corporation $IRMD
HighTower Advisors LLC significantly reduced its stake in iRadimed Corporation (NASDAQ:IRMD) by selling 20,000 shares, decreasing its position by 33.1%. Despite this sale, iRadimed reported strong financial results, surpassing EPS and revenue expectations, and increased its quarterly dividend. The company maintains a "Moderate Buy" consensus rating from Wall Street analysts, with an average price target of $120.
IRMD Stock News Today | Earnings, Events & Price Alerts
This article provides news and event updates for IRadimed (IRMD) stock, highlighting recent financial performance and analyst commentary. Key news includes Nine Ten Capital Management selling shares, IRadimed reporting record revenue for the 18th consecutive quarter, strong Q4 2025 earnings, a dividend increase, and an upcoming Q4 earnings release. An event summary details mixed market performance, top news, Wall Street calls, industry updates, and stock movers from February 10, 2026.
Is It Too Late To Reassess IRADIMED (IRMD) After Its Strong Multi‑Year Share Price Run?
This article evaluates IRADIMED (IRMD) to determine if its current share price reflects overvaluation despite strong multi-year returns. Using a Discounted Cash Flow (DCF) analysis and Price-to-Earnings (P/E) ratio comparison, Simply Wall St suggests the stock is significantly overvalued, trading at US$100.50 against an intrinsic value of $33.19 per share and a "Fair Ratio" P/E of 19.01x versus its current 56.87x. The article encourages investors to conduct their own analysis through "Narratives" on the platform.
Here’s What Offers IRadimed Corp. (IRMD) a Compelling Growth Trajectory
Conestoga Capital Advisors highlighted IRADIMED CORPORATION (NASDAQ: IRMD) in its Q4 2025 investor letter, noting the company's strong operational performance, record third-quarter revenue and earnings, and a special cash dividend. Despite trailing the Russell Microcap Growth Index, Conestoga believes IRMD's niche leadership in MRI-compatible medical devices and innovative product pipeline offer a compelling growth trajectory. The article notes that while IRMD shows promise, some AI stocks may offer higher returns in a shorter timeframe.
IRadimed Stock Up 80% in One Year as Fund Sells $29 Million Stake Amid Record Quarter
Nine Ten Capital Management sold 342,907 shares of IRadimed (NASDAQ:IRMD), valued at an estimated $29.42 million, during the fourth quarter of 2025. Despite the sale, IRadimed's stock has risen 83% over the past year, reflecting its strong financial performance, including 18 consecutive quarters of record revenue and increased dividends. The fund's decision to trim its stake is attributed to portfolio discipline rather than a lack of confidence in the company's fundamentals, as it still represents 13.2% of their assets under management.
Allen Monty K sells IRADIMED (IRMD) shares worth $100,256 By Investing.com
IRADIMED Director Allen Monty K sold 1,000 shares of IRADIMED CORP (NASDAQ:IRMD) worth $100,256 on February 13, 2026, when the stock was trading near its 52-week high. Despite the sale, IRADIMED received a "GREAT" financial health rating from InvestingPro and is expected to remain profitable, following impressive Q4 2025 earnings that surpassed analyst expectations.
IRADIMED Corp (IRMD) director sells 1,000 shares at $100.2563
IRADIMED Corp director Monty K. Allen sold 1,000 shares of company common stock on February 13, 2026, in an open-market transaction. The shares were sold in multiple trades at a weighted average price of $100.2563 per share. Following this transaction, Allen directly owns 21,000 shares of IRADIMED CORP common stock.
Allen Monty K sells IRADIMED (IRMD) shares worth $100,256 By Investing.com
Director Allen Monty K has sold 1,000 shares of IRADIMED (NASDAQ:IRMD) for a total of $100,256, with shares trading near their 52-week high and showing an 83.6% return over the past year. Despite a strong financial health rating and expected profitability, InvestingPro suggests the stock may be overvalued with a P/E ratio of 57.5. This transaction follows the company's impressive fourth-quarter 2025 earnings, which exceeded analyst expectations.
Allen Monty K sells IRADIMED (IRMD) shares worth $100,256
Director Allen Monty K sold 1,000 shares of IRADIMED CORP (NASDAQ:IRMD) for $100,256 on February 13, 2026. This transaction occurred as the stock trades near its 52-week high and has shown an 83.6% return over the past year. Despite a P/E ratio of 57.5, suggesting potential overvaluation, the company recently reported strong fourth-quarter 2025 earnings, exceeding analyst expectations.
Director Monty Allen Sells 1,000 Shares of iRadimed Corp (IRMD)
Monty Allen, a Director at iRadimed Corp (IRMD), sold 1,000 shares of the company on February 13, 2026, reducing his holdings to 21,000 shares. This transaction follows a pattern of 26 insider sells and no buys over the past year. The stock is currently trading at $100.26, indicating it is significantly overvalued with a price-to-GF-Value ratio of 1.67 and a P/E ratio of 57.03 compared to an industry median of 28.48.
IRADIMED Record Revenue Streak Supports 3870 Pump Rollout And Dividend Growth
IRADIMED (NasdaqGM:IRMD) announced its 18th consecutive quarter of record revenue and the full rollout of its 3870 MRI compatible IV infusion pump, alongside an increased quarterly dividend. The company has shown strong stock performance over the past five years, and the new pump is expected to drive further growth in Europe and Japan. While analysts see potential, Simply Wall St's valuation indicates the stock is currently trading significantly above its estimated fair value.
IRADIMED Dividend Hike Follows Record Revenue And New MRI Pump Rollout
IRADIMED (NasdaqGM:IRMD) announced an increased quarterly dividend to US$0.20 per share, following 18 consecutive quarters of record revenue and strong double-digit growth in sales and earnings. The company is experiencing robust adoption of its existing MRI-compatible devices and is shipping its new 3870 infusion pump, with management confident in future product launches and domestic replacement demand. While the dividend hike signals strong financial health, investors are advised to monitor the rollout and potential competitive pressures, especially given recent insider selling.
Iradimed Corp Eyes 2026 Surge After Strong Quarter
Iradimed Corp reported record Q4 2025 revenue of $22.7 million, up 17% year over year, with full-year sales reaching $83.8 million, a 14% increase. The company is launching its new 3870 MR IV pump, expecting a 10%-14% higher average selling price and targeting a $100 million-plus revenue run rate in 2026 from the significant U.S. replacement market. While the transition may bring near-term margin pressure and international launch delays, the company is optimistic about sustained growth and future R&D in a next-generation MRI monitor.
IRadimed Corporation (NASDAQ:IRMD) Q4 2025 Earnings Call Transcript
IRadimed Corporation reported record revenues of $22.7 million in Q4 2025, a 17% increase year-over-year, and $83.8 million for the full year 2025. The company's new 3870 MR IV pump is expected to be a significant growth driver, targeting a large replacement opportunity in the U.S. market. IRadimed anticipates reaching a $100 million-plus annual revenue run rate during 2026, driven by the new pump and continued growth in other product lines.
iRadimed Corporation (NASDAQ:IRMD) to Issue Quarterly Dividend of $0.20
iRadimed Corporation (NASDAQ:IRMD) declared a quarterly dividend of $0.20 per share, a 17.6% increase from its previous dividend, resulting in an 0.8% yield. The medical equipment provider's shares rose by 9.3% after reporting better-than-expected Q4 earnings of $0.54 EPS on revenues of $22.69 million. The company also provided strong guidance for Q1 and FY2026, indicating sufficient coverage for the increased dividend.
IRADIMED CORPORATION Reports Record Fourth Quarter and Full
IRADIMED CORPORATION announced record financial results for the fourth quarter and full year of 2025, with revenue reaching $22.7 million for Q4 (17% increase) and $83.8 million for the full year (14% increase). The company also increased its regular quarterly cash dividend to $0.20 per share, reflecting confidence in its business outlook. This growth was driven by the successful shipment of initial 3870 units and expected full rollout of the next-generation MRI-compatible IV infusion pump in early 2026, alongside positive financial guidance for 2026.
Iradimed Stock Surges as Record Quarterly Revenue Streak Hits 18
Iradimed Corporation (IRMD) shares surged by 9.26% after reporting its 18th consecutive quarter of record revenue, reaching $22.7 million in Q4 2025 – a 17% increase year-over-year. Non-GAAP net income also grew by 23% to $7.0 million, or $0.54 per share, surpassing analyst expectations. The company also announced an increased quarterly dividend and provided optimistic revenue guidance for 2026, projecting $91 million to $96 million.
IRADIMED (NASDAQ: IRMD) delivers record 2025 results and boosts dividend with strong 2026 outlook
IRADIMED Corporation (NASDAQ: IRMD) reported record financial results for the fourth quarter and full year 2025, with revenue up 17% and 14% respectively, and net income seeing significant increases. The company announced a dividend increase from $0.17 to $0.20 per share and provided robust guidance for 2026, anticipating revenue between $91.0 million and $96.0 million, driven by the rollout of its next-generation MRI-compatible IV infusion pump. These strong results and positive outlook reflect the company's focus on innovation and operational efficiency.
IRadimed: Fourth Quarter Financial Highlights
IRadimed Corp. announced a net profit of $6.4 million for the fourth quarter, with earnings of 50 cents per share and adjusted earnings of 54 cents per share. The company, which manufactures IV devices for MRI equipment, achieved $22.7 million in revenue for the quarter and $83.8 million for the full year. For the upcoming first quarter, IRadimed anticipates earnings per share between 44 and 48 cents, with projected revenue of $21 million to $22 million.
IRADIMED ($IRMD) Releases Q4 2025 Earnings
IRADIMED ($IRMD) reported its Q4 2025 earnings, surpassing analyst expectations with earnings of $0.54 per share against estimates of $0.49, and revenue of $22.69 million against estimates of $22.032 million. The article also details significant insider selling activity, with CEO Roger E. Susi selling a substantial number of shares, and provides an overview of hedge fund activity and government contracts for IRADIMED.
IRadimed: Fourth Quarter Financial Highlights
IRadimed Corp. announced its fourth-quarter financial results, reporting a net income of $6.4 million and adjusted earnings of 54 cents per share on $22.7 million in revenue. For the full year, the company achieved a net profit of $22.5 million and $83.8 million in total revenue. IRadimed projects first-quarter earnings per share between 44 and 48 cents and revenue between $21 million and $22 million.
IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results
IRADIMED CORPORATION announced record financial results for the fourth quarter and full year of 2025, driven by strong operational performance and strategic initiatives. The company reported significant increases in revenue and diluted EPS, successfully launched its next-generation MRI-compatible IV infusion pump, and declared an increased quarterly cash dividend. IRADIMED also provided an optimistic outlook for revenue and EPS for the first quarter and full year of 2026.
IRadimed: Q4 Earnings Snapshot
IRadimed Corp. (IRMD) reported a net income of $6.4 million, or 50 cents per share, in its fourth quarter, with adjusted earnings of 54 cents per share. The company generated revenue of $22.7 million for the period. For the full year, IRadimed's profit was $22.5 million, or $1.75 per share, on $83.8 million in revenue, and it provided a first-quarter earnings outlook of 44 to 48 cents per share on revenue between $21 million and $22 million.
IRadimed: Fourth Quarter Financial Highlights
IRadimed Corp. reported a net profit of $6.4 million for the fourth quarter, with earnings of 50 cents per share and adjusted earnings of 54 cents per share, on revenue of $22.7 million. For the full year, the company achieved a profit of $22.5 million ($1.75 per share) and $83.8 million in revenue. Looking ahead, IRadimed forecasts first-quarter earnings per share between 44 and 48 cents and revenue of $21 million to $22 million.
IRadimed: Fourth Quarter Financial Highlights
IRadimed Corp. announced its fourth-quarter financial results, reporting a net income of $6.4 million and adjusted earnings of 54 cents per share. The company generated $22.7 million in revenue for the quarter. For the full year, IRadimed achieved a net profit of $22.5 million on $83.8 million in revenue, and projects first-quarter earnings per share between 44 and 48 cents with revenue between $21 million and $22 million.
Analysts Are Bullish on Top Healthcare Stocks: Iradimed (IRMD), Inotiv (NOTV)
Two healthcare stocks, Iradimed (IRMD) and Inotiv (NOTV), have received bullish sentiments from analysts. Frank Takkinen from Lake Street reiterated a Buy rating on Iradimed with a $100.00 price target, while Matt Hewitt from Craig-Hallum maintained a Buy rating on Inotiv. Both companies currently hold a Moderate Buy consensus among analysts.
Ranger Investment Management L.P. Lowers Stake in iRadimed Corporation $IRMD
Ranger Investment Management L.P. significantly reduced its stake in iRadimed Corporation (NASDAQ:IRMD) by 44.3% in the third quarter, selling over 95,000 shares. Despite this, other institutional investors have either increased or initiated positions in the medical equipment provider. iRadimed, with a market capitalization of $1.22 billion, recently beat EPS estimates, paid a special dividend, and maintains a "Moderate Buy" consensus rating among analysts, even as company insiders have sold shares.
The total return for IRADIMED (NASDAQ:IRMD) investors has risen faster than earnings growth over the last five years
IRADIMED (NASDAQ:IRMD) shareholders have seen a 280% price increase over five years, accompanied by 38% annual EPS growth. However, the total shareholder return (TSR), which includes reinvested dividends, was even higher at 316% over the same period, indicating dividends played a significant role. Recently, the one-year TSR of 57% has surpassed the five-year average, suggesting improved sentiment around the company.
IRADIMED CORPORATION to Hold Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 10, 2026
IRADIMED CORPORATION (NASDAQ: IRMD) will announce its fourth quarter and full year 2025 financial results before the market opens on Tuesday, February 10, 2026. Company management will host a conference call on the same day at 11:00 a.m. Eastern Time to discuss the results and answer questions. Investors can register online for dial-in details or access a real-time webcast, with a recording to be made available on the company's investor website afterward.
